Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07395687 | A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity | PHASE2 | RECRUITING | 333 | — | — | Feb 2, 2026 | Feb 18, 2027 | Apr 21, 2026 | 3 | United States, Canada |
Measured as Number of events.
Measured as percentage of body weight.
Measured as hour\*nanomoles per liter (h\*nmol/L)
| Arm | Type | Description |
|---|---|---|
| Part A - UBT251 | EXPERIMENTAL | Participants will be randomized to receive multiple dose levels subcutaneously. |
| Part A - placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to UBT251 subcutaneously. |
| Part B - Arm A (UBT251) | EXPERIMENTAL | Participants will be randomized to receive multiple dose levels subcutaneously. |
| Part B - Arm B (UBT251) | EXPERIMENTAL | Participants will be randomized to receive multiple dose levels subcutaneously. |
| Part B - Arm C (UBT251) | EXPERIMENTAL | Participants will be randomized to receive multiple dose levels subcutaneously. |
| Part B - Arm D (UBT251) | EXPERIMENTAL | Participants will be randomized to receive 2 dose levels subcutaneously. |
| Part B - Arm E (UBT251) | EXPERIMENTAL | Participants will be randomized to receive a single dose level subcutaneously. |
| Part B - placebo | PLACEBO_COMPARATOR | Participants will receive placebo matching one of the UBT251 arms subcutaneously. |
| Part C - UBT251 dose 1 | EXPERIMENTAL | Participants will be randomized to receive dose level 1 subcutaneously. |
| Part C - UBT251 dose 2 | EXPERIMENTAL | Participants will be randomized to receive dose level 2 subcutaneously. |
| Part C - UBT251 dose 3 | EXPERIMENTAL | Participants will be randomized to receive dose level 3 subcutaneously. |
| Name | Type | Description |
|---|---|---|
| UBT251 | DRUG | UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin. |
| Placebo | DRUG | Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin. |
Inclusion Criteria: 1. Male or female (sex at birth). 2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported): * For Japanese participants: both parents of Japanese descent. * For Chinese participants: both parents of Chinese descent. * For non-Asian participants: b...